BridgeBio Oncology Therapeutics, Inc. SEC filings BBOT
BridgeBio Oncology Therapeutics, Inc. has 185 filings in SEC EDGAR's recent list, going back to Dec 20, 2023. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 5, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 22, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 29, 2026 | Apr 27, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 23, 2026 | Apr 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 26, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Other events
|
Jan 7, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Aug 13, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 11, 2025 | Jul 11, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 3, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 28, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Officer or director change
|
Feb 10, 2025 | Feb 8, 2025 |
| 8-K |
Current report
Other events
|
Feb 20, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Feb 14, 2024 | Feb 8, 2024 |
Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BBOT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1869105
- Former names
- Helix Acquisition Corp. II (until Aug 6, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.